After 37 years of pioneering health journalism, community engagement, and empowerment through information, we have now ceased operations.
This website will be accessible until September 2025, with all the information being up to date as of July 2024.
If you are a supplier, or another partner you can contact our legacy email address as aidsmap@outlook.com with any queries.
We extend our heartfelt thanks to everyone who supported our vision for a world where HIV is no longer a threat to health or happiness. Together we have made a difference.
IAS 2021: Injectable treatment for multidrug-resistant HIV
Professor Jean-Michel Molina of Hôpital Saint-Louis in Paris talks about injectable lenacapavir, a capsid inhibitor currently under development, for people with multidrug-resistant HIV at IAS 2021.
